FEM-1689
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
FEM-1689 is an experimental drug developed for the treatment of neuropathic pain. It acts as a potent and selective sigma-2 receptor ligand with a binding affinity of 11 nM, indicating its strong potential in targeting and modulating the sigma-2 receptor pathway.
Mechanism of Action[edit | edit source]
FEM-1689 exerts its effects by selectively binding to the sigma-2 receptor, a protein associated with the modulation of pain perception and neuronal signaling. Through its action on this receptor, FEM-1689 is believed to offer therapeutic benefits in conditions characterized by neuropathic pain, altering pain transmission and potentially providing relief from chronic pain conditions.
Development and Research[edit | edit source]
The development of FEM-1689 is based on the identification of sigma-2 receptors as potential targets for neuropathic pain management. Preclinical studies have focused on evaluating its efficacy, safety profile, and mechanism of action. As of now, FEM-1689 remains under investigation, with ongoing research aimed at determining its clinical applicability, optimal dosing, and potential side effects.
Clinical Trials[edit | edit source]
To date, detailed information on clinical trials involving FEM-1689 is limited. Further research and clinical studies are necessary to fully understand its therapeutic potential and to ensure its safety and efficacy in humans.
Potential Applications[edit | edit source]
Beyond neuropathic pain, the selective targeting of sigma-2 receptors by FEM-1689 may hold promise for other neurological and psychiatric disorders where sigma-2 receptors play a role. However, the exploration of these additional applications is contingent upon gaining a deeper understanding of the drug's pharmacodynamics and successful clinical outcomes.
See also[edit | edit source]
| FEM-1689 Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
